Diagnostic and therapeutic applications of iontophoresis

Journal of Drug Targeting

Volumn 17, Issue 9, 2009, Pages 690-700

  Sieg, Anke ^a   Wascotte, Valentine ^b  

^a Dow Corning SA Belgium   (Belgium)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

electrically assisted delivery; Iontophoresis; nail; skin; therapeutic monitoring; topical; transdermal drug delivery

Indexed keywords

ACICLOVIR; ADRENALIN; ALNIDITAN; APOMORPHINE; BUPRENORPHINE; CATION; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; DEXAMETHASONE; DICLOFENAC; FENTANYL; FLUOROURACIL; GLUCOSE; HYDROMORPHONE; KETOPROFEN; LIDOCAINE; METHOTREXATE; MORPHINE; NALBUPHINE; PILOCARPINE; PIROXICAM; PREDNISOLONE; PRILOCAINE; ROPINIROLE; SUMATRIPTAN; TACRINE; UNINDEXED DRUG; VINBLASTINE SULFATE; XENOBIOTIC AGENT; ZOLMITRIPTAN; DRUG;

ALZHEIMER DISEASE; BLOOD GLUCOSE MONITORING; CHRONIC PAIN; DIABETES MELLITUS; DIFFUSION; DRUG DELIVERY SYSTEM; ELECTRIC FIELD; ELECTRICITY; ELECTRODE; ELECTROOSMOSIS; EXTRACTION; HERPES LABIALIS; HUMAN; HYPERHIDROSIS; ION TRANSPORT; IONTOPHORESIS; LIMIT OF QUANTITATION; LOCAL ANESTHESIA; MEMBRANE DAMAGE; MIGRAINE; NON INVASIVE PROCEDURE; OXIDATION REDUCTION REACTION; PAIN; PARKINSON DISEASE; PH; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN; SKIN CANCER; SKIN IRRITATION; STRATUM CORNEUM; DRUG MONITORING; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PHARMACEUTICS; SKIN ABSORPTION; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, CUTANEOUS; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; DRUG MONITORING; HUMANS; IONTOPHORESIS; PHARMACEUTICAL PREPARATIONS; SKIN; SKIN ABSORPTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 73449093240     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903089750     Document Type: Review

References (107)

1. Alvarez-Figueroa MJ, Delgado-Charro MB, Blanco-Mendez. (2001). Passive and iontophoretic penetration of methotrexate. Int J Pharm, 212, 101-107.
2. Ashburn M, Stepehen RL, Ackerman E, Petelenz TJ, Hare B, Pace NL, Hofman AA. (1992). Iontophoretic delivery of morphine for postoperative analgesia. J Pain Sympt Manage, 7, 27-33.
3. Banga A. (1998). Clinical applications of iontophoresis devices for topical dermatological delivery. In: Electrically Enhanced Transdermal Drug Delivery (pp. 57-74). London, UK: Taylor & Francis.
4. Banga AK, Katakam M, Mitra R. (1995). Transdermal iontophoretic delivery and degradation of vasopressin across human cadaver skin. Int J Pharm, 116, 211-216.
5. Bose S, Ravis WR, Lin YL, Zhang L, Hofmann GA, Banga AK. (2001). Electrically-assisted transdermal delivery of buprenorphine. J Control Release, 73, 197-203. (Pubitemid 32539248)
6. Brand RM, Guy RH. (1995). Iontophoresis of nicotine in vitro: pulsatile drug delivery across the skin? J Control Release, 33, 285-292.
7. Burnette RR. (1989). Iontophoresis. In: Hadgraft J, Guy RH, eds. Transdermal Delivery Systems: Developmental Issues and Research Initiatives (pp. 247-291). New York: Marcel Dekker.
8. Chang BK, Guthrie TH, Hayakawa K, Gangarosa LP. (1993). A pilot study of iontophoretic cisplatin chemotherapy of basal and squamous cell carcinomas of the skin. Arch Dermatol, 129, 425-427. (Pubitemid 23118237)
9. Cormier M, Chao ST, Gupta SK, Haak R. (1999). Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. J Pharm Sci, 88, 1030-1035. (Pubitemid 29480595)
10. Craane-van Hinsberg WH, Bax L, Flinterman NH, Verhoef J, Junginger HE, Bodde HE. (1994). Iontophoresis of a model peptide across human skin in vitro: effects of iontophoresis protocol, pH, and ionic strength on peptide flux and skin impedance. Pharm Res, 11, 1296-1300. (Pubitemid 24287409)
11. Curdy C, Kalia YN, Guy RH. (2001). Noninvasive assessment of the effects of iontophoresis on human skin in vivo. J Pharm Pharmacol, 53, 769-777. (Pubitemid 32529719)
12. Curdy C, Kalia YN, Naik A, Guy RH. (2001). Piroxicam delivery into human stratum corneum in vivo: iontophoresis versus passive diffusion. J Control Release, 76, 73-79. (Pubitemid 32786886)
13. Degim IT, Ilbasmis S, Dundaroz R, Oguz Y. (2003). Reverse iontophoresis: a non-invasive technique for measuring blood urea level. Pediatr Nephrol, 18, 1032-1037. (Pubitemid 37236218)
14. Delgado-Charro MB. (2009). Recent advances on transdermal iontophoretic drug delivery and non-invasive sampling. J Drug Deliv Sci Tech, 19, 75-88.
15. Delgado-Charro MB, Guy RH. (1995). Iontophoretic delivery of nafarelin across the skin. Int J Pharm, 117, 165-172.
16. Delgado-Charro MB, Guy RH. (2001). Transdermal iontophoresis for controlled drug delivery and non-invasive monitoring. S T P Pharm Sci, 11, 403-14. (Pubitemid 34016285)
17. Delgado-Charro MB, Guy RH. (2003). Transdermal reverse iontophoresis of valproate: a noninvasive method for therapeutic drug monitoring. Pharm Res, 20, 1508-1513. (Pubitemid 37164061)
18. DiabetesNet.com. (2008). Animas GlucoWatch Update. Last accessed, April 8, 2009, at http://www.diabetesnet.com/diabetes-technology/glucowatch.php.
19. Eastman RC, Chase HP, Buckingham B, Hathout EH, Fuller-Byk L, Leptien A, Van Wyhe MM, Davis TL, Fermi SJ, Pechler H, Sahyun G, Lopatin M, Wang BY, Wei C, Bartkowiak M, Ginsberg BH, Tamada JA, Pitzer KR. (2002). Use of the GlucoWatch Biographer in children and adolescents with diabetes. Pediatr Diabetes, 3, 127-134. (Pubitemid 35203519)
20. Eljarrat-Binstock E, Domb AJ. (2006). Iontophoresis: a non-invasive ocular drug delivery. J Control Release, 10, 479-489. (Pubitemid 43163439)
21. Ellens H, Lai Z, Marcello J, Davis CB, Cheng HY, Oh, CK, Okabe K. (1997). Transdermal iontophoretic delivery of (3H)GHRP in rats. Int J Pharm, 159, 1-11. (Pubitemid 28062804)
22. EMEA. (2005). Last accessed, March 28, 2009, at http://www.emea.europa. eu/humandocs/Humans/EPAR/ionsys/ionsys.htm.
23. EMEA. (2007). Last accessed, March 28, 2009, at http://www.emea.europa. eu/humandocs/PDFs/EPAR/ionsys/061206en6.pdf.
24. Fang JY, Sung KC, Lin HH, Fang CL. (1999). Transdermal iontophoretic delivery of diclofenac sodium from various polymer formulations: in vitro and in vivo studies. Int J Pharm, 178, 83-92. (Pubitemid 29074410)
25. Galinkin JL, Rose JB, Harris K, Watcha MF. (2002). Lidocaine iontophoresis versus eutectic mixture of local anesthetics (EMLA) for IV placement in children. Anesth Analg, 94, 1484-1489.
26. Gangarosa LP, Ozawa A, Ohkido M, Shimomura Y. (1995). Iontophoresis for enhancing penetration of dermatologic and antiviral drugs. J Dermatol, 22, 865-875. (Pubitemid 26010663)
27. Gibson LE, Cooke RE. (1959). A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics, 23, 545-549.
28. Glikfeld P, Hinz RS, Guy RH. (1989). Noninvasive sampling of biological fluids by iontophoresis. Pharm Res, 6, 988-990. (Pubitemid 20078453)
29. Gupta SK, Southam M, Sathyan G, Klasuner M. (1998). Effect of current density on pharmacokinetics following continuous or intermittent input from fentanyl electrotransport system. J Pharm Sci, 87, 976-981. (Pubitemid 28381255)
30. Hao J, Li SK. (2008a). Transungual iontophoretic transport of polar neutral and positively charged model permeants: effects of electrophoresis and electroosmosis. J Pharm Sci, 97, 893-905. (Pubitemid 351293889)
31. Hao J, Li SK. (2008b). Mechanistic study of electorosmotic transport across hydrated nail plates: effects of pH and ionic strength. J Pharm Sci, 97, 5186-5197.
32. Heit MC, Monteiro-Riviere NA, Jayes FL, Riviere JE. (1994). Transdermal iontophoretic delivery of luteinizing hormone releasing hormone: effect of repeated administration. Pharm Res, 11, 1000-1003. (Pubitemid 24227646)
33. Herndon CM. (2007). Iontophoretic drug delivery system: focus on fentanyl 2007. Pharmacotherapy, 27, 745-754. (Pubitemid 46700967)
34. Hirvonen J, Guy RH. (1997). Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. Pharm Res, 14, 1258-1263. (Pubitemid 27432553)
35. Holzle E, Alberti N. (1987). Long-term efficacy and side effects of tap water iontophoresis of palmoplantar hyperhidrosis-the usefulness of home therapy. Dermatologica, 175, 126-135. (Pubitemid 17126920)
36. Irsfeld S, Klement W, Lipfert P. (1993). Dermal anesthesia: comparison of EMLA cream with iontophoretic local anaesthesia. Br J Anaesth, 71, 375-378. (Pubitemid 23268880)
37. Jadoul A, Preat V. (1997). Electrically-enhanced transdermal delivery of domperidone. Int J Pharm, 154, 229-234.
38. Jadoul A, Bouwstra J, Preat V. (1999). Effects of iontophoresis and electroporation on the stratum corneum. Review of the biophysical studies. Adv Drug Del Rev, 35, 89-105. (Pubitemid 29046388)
39. Jadoul A, Mesens, Caers W, de Beukelaar F, Crabbe R, Preat V. (1996). Transdermal permeation of alniditan by iontophoresis: in vitro optimization and human pharmacokinetic data. Pharm Res, 23, 175-182.
40. Jain A, Ghosh B, Rajgor N, Desai BG. (2008). Passive and iontophoretic permeation of glipizide. Eur J Pharm Biopharm, 69, 958-963.
41. Jain KK. (2008). Transdermal Drug Delivery. Technologies, Companies & Markets. A Jain Pharma Biotech Report.
42. James MP, Graham RM, English J. (1986). Percutaneous iontophoresis of prednisolone-a pharmacokinetic study. Clin Exp Dermatol, 11, 54-61. (Pubitemid 16201375)
43. Kalia YN, Naik A, Garrison J, Guy RH. (2004). Iontophoretic drug delivery. Adv Drug Del Rev, 56, 619-658. (Pubitemid 38326937)
44. Kanikkannan N, Singh J, Ramarao P. (2000). Transdermal iontophoretic delivery of timolol maleate in albino rabbits. Int J Pharm, 197, 69-76. (Pubitemid 30125778)
45. Kankkunen T, Sulkava R, Vuorio M Kontturi K, Hirvonen J. (2002). Transdermal iontophoresis of tacrine in vivo. Pharm Res, 19, 704-707. (Pubitemid 34553681)
46. Kasha PC, Banga AK. (2008). A review of patent literature for iontophoretic delivery and devices. Recent Patents Drug Deliv Formul, 2, 41-50. (Pubitemid 351546433)
47. Langkjaer L, Brange J, Grodsky GM, Guy RH. (1998). Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. J Control Release, 51, 47-56. (Pubitemid 28064644)
48. Lau DT, Sharkey JW, Petryk L, Mancuso FA, Yu Z, Tse FL. (1994). Effect of current magnitude and drug concentration on iontophoretic delivery of octreotide acetate (Sandostatin) in the rabbit. Pharm Res, 11, 1742-1746. (Pubitemid 24377085)
49. Leboulanger B, Aubry JM, Bondolfi G, Guy RH, Delgado-Charro MB. (2004a). Lithium monitoring by reverse iontophoresis in vivo. Clin Chem, 50, 2091-2100. (Pubitemid 39425847)
50. Leboulanger B, Guy RH, Delgado-Charro MB. (2004b). Non-invasive monitoring of phenytoin by reverse iontophoresis. Eur J Pharm Sci, 22, 427-433. (Pubitemid 38953901)
51. Leboulanger B, Guy RH, Delgado-Charro MB. (2004c). Reverse iontophoresis for non-invasive transdermal monitoring. Physiol Meas, 25, R35-50. (Pubitemid 38901997)
52. Ledger PW. (1992). Skin biological issues in electrically enhanced transdermal delivery. Adv Drug Deliv Rev, 9, 289-307.
53. Leduc S. (1900). Introduction of medicinal substances into the depth of tissues by electric current. Ann Electrobiol, 3, 545-560.
54. Longo N, Li SK, Yan G, Kochambilli RP, Papangkorn K, Berglund D, Ghanem AH, Ashurst CL, Ernst SL, Pasquali M, Higuchi WI. (2007). Noninvasive measurement of phenylalanine by iontophoretic extraction in patients with phenylketonuria. J Inherit Metab Dis, 30, 910-915. (Pubitemid 350263131)
55. Li CM, Dong H, Cao X, Luong JH, Zhang X. (2007). Implantable electrochemical sensors for biomedical and clinical applications: progress, problems, and future possibilities. Curr Med Chem, 14, 937-951. (Pubitemid 46863620)
56. Lopez RF, Bentley MV, Delgado-Charro MB, Guy RH. (2001). Iontophoretic delivery of 5-aminolevulinic acid (ALA): effect of pH. Pharm Res, 18, 311-315. (Pubitemid 32595818)
57. Lu MF, Lee D, Carlson R, Rao GS, Hui HW, Adjei L, Herrin M, Sundberg D, Hsu L. (1993). The effects of formulation variables on iontophoretic transdermal delivery of leuprolide to humans. Drug Dev Ind Pharm, 19, 1557-1571. (Pubitemid 23179148)
58. Luzardo-Alvarez A, Delgado-Charro MB, Blanco-Mendez J. (2001). Iontophoretic delivery of ropinirole hydrochloride: effect of current density and vehicle formulation. Pharm Res, 18, 1714-1720. (Pubitemid 34020427)
59. Marconi B, Mancini F, Colombo P, Allegra F, Giordano F, Gazzaniga A, Orecchia G, Santi P. (1999). Distribution of khellin in excised human skin following iontophoresis and passive dermal transport. J Control Release, 60, 261-268. (Pubitemid 29335951)
60. Marro D, Kalia YN, Delgado-Charro MB, Guy RH. (2001). Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm Res, 18, 1701-1708. (Pubitemid 34020425)
61. Merino V, Lopez A, Hochstrasser D, Guy RH. (1999). Noninvasive sampling of phenylalanine by reverse iontophoresis. J Control Release, 61, 65-69. (Pubitemid 29406080)
62. Mize NK, Buttery M, Daddona P, Morales C, Cormier M. (1997). Reverse iontophoresis: monitoring prostaglandin E2 associated with cutaneous inflammation in vivo. Exp Dermatol, 6, 298-302. (Pubitemid 27505171)
63. Murdan S. (2008). Enhancing the nail permeability of topically applied drugs. Exp Opin Drug Deliv, 5, 1-16.
64. Murthy SN, Waddell DC, Shivakumar HN, Balaji A, Bowers CP. (2007a). Iontophoretic permselective property of human nail. J Dermatol Sci, 46, 150-152. (Pubitemid 46467285)
65. Murthy SN, Wiskirchen DE, Bowers CP. (2007b). Iontophoretic delivery across human nail. J Pharm Sci, 96, 305-311. (Pubitemid 46363561)
66. Nair AB, Kim H, Chakraborty B, Singh J, Zaman M, Gupta A, Friden P, Murthy N. (2009a) DOI:10.1002/jps.21711. Ungual and transungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci, 98.
67. Nair AB, Vaka SRK, Sammeta SM, Kim HD, Friden PM, Murthy N. (2009b). Trans-ungual iontophoretic delivery of terbinafine. J Pharm Sci, 98(5), 1788-1796.
68. Nakakura M, Kato Y, Hayakawa E, Ito K, Kuroda T. (1996). Effect of pulse on iontophoretic delivery of desmopressin acetate in rats. Biol Pharm Bull, 19, 738-740. (Pubitemid 26187887)
69. Nixon S, Sieg A, Delgado-Charro MB, Guy RH. (2007). Reverse iontophoresis of l-lactate: in vitro and in vivo studies. J Pharm Sci, 96, 3457-3465.
70. Oh SY, Jeong SY, Park TG, Lee JH. (1998). Enhanced transdermal delivery of AZT (zidovudine) using iontophoresis and penetration enhancer. J Control Release, 51, 161-168. (Pubitemid 28252867)
71. Padmanabhan RV, Phipps JB, Lattin GA, Sawchuk RJ. (1990). In vitro and in vivo evaluation of transdermal iontophoretic delivery of hydromorphone. J Control Release, 11, 123-135. (Pubitemid 20070091)
72. Panus PC, Campbell J, Kulkarni SB, Herrick RT, Ravis WR, Banga AK. (1997). Transdermal iontophoretic delivery of ketoprofen through human cadaver skin and in humans. J Control Release, 44, 113-121. (Pubitemid 27039108)
73. Patel SR, Zhong H, Sharma A, Kalia YN. (2007). In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptane succinate. Eur J Pharm Biopharm, 66, 296-301. (Pubitemid 46661905)
74. Patel SR, Zhong H, Sharma A, Kalia YN. (2009). Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo. Eur J Pharm Biopharm, 72, 304-309.
75. Pennington P, Caminiti S, Schein JR, Hewitt DJ, Nelson WW. (2009). Patients' assessment of the convenience of fentanyl HCl iontophoretic transdermal system (ITS) versus morphine intravenous patient-controlled analgesia. Pain Manag Nurs, doi: 10.1016/j. pmn.2007.09.001.
76. Phipps JB, Padmanabhan RV, Young W, Panos R, Chester AE. (2003). E-TRANS technology. In: Drugs and the Pharmaceutical Sciences: Editors, Rathbone M, Hadgraft J, Roberts M. (Modified- Release Drug Delivery Technology) (vol. 126, pp. 499-511). New York: Marcel Dekker.
77. Pikal MJ. (1992). The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Del Rev, 9, 201-237.
78. Rao G, Glikfeld P, Guy RH. (1993) Reverse iontophoresis: development of a non invasive approach for glucose monitoring. Pharm Res, 10, 1751-1755. (Pubitemid 24000360)
79. Rao G, Guy RH, Glikfeld P, LaCourse WR, Leung L, Tamada J, Potts RO, Azimi N. (1995). Reverse iontophoresis: non invasive glucose monitoring in vivo in humans. Pharm Res, 12, 1869-1873. (Pubitemid 26031771)
80. Riviere JE, Monteiro-Riviere NA, Inman AO. (1992a). Determination of lidocaine concentrations in skin after transdermal iontophoresis: effect of vasoactive drugs. Pharm Res, 9, 211-214.
81. Riviere JE, Williams PL, Hillman RS, Mishky LM. (1992b). Quantitative prediction of transdermal iontophoretic delivery of arbutamine in humans with the in vitro isolated perfused procine skin flap. J Pharm Sci, 81, 504-507.
82. Santi P, Guy., RH. (1996). Reverse iontophoresis-parameters determining electroosmotic flow: I. pH and ionic strength. J Control Release, 38, 159-165. (Pubitemid 26096660)
83. Scott ER, Phipps JB, Gyory JR, Padmanabhan RV. (2000). Electrotransport systems for transdermal delivery: a practical implementation of iontophoresis In: Wise DL, ed. Handbook of Pharmaceutical Controlled Release Technology (pp. 617-659.). New York: Marcel Dekker.
84. Shukla C, Friden P, Juluru R, Stagni G. (2008). In vivo quantification of acyclovir exposure in the dermis following iontophoresis of semisolid formulations. J Pharm Sci, 98, 917-925.
85. Sekkat N, Naik A, Kalia YN, Glikfeld P, Guy RH. (2002). Reverse iontophoretic monitoring in premature neonates: feasibility and potential. J Control Release, 81, 83-89. (Pubitemid 34454852)
86. Sieg A, Guy RH, Delgado-Charro MB. (2004a). Noninvasive glucose monitoring by reverse iontophoresis in vivo: application of the internal standard concept. Clin Chem, 50, 1383-1390. (Pubitemid 38970646)
87. Sieg A, Guy RH, Delgado-Charro MB. (2004b). Simultaneous extraction of urea and glucose by reverse iontophoresis in vivo. Pharm Res, 21, 1807-1812.
88. Sieg A, Delgado-Charro MB, Guy RH. (2005). Noninvasive and minimally invasive methods for transdermal glucose monitoring. Diabet Technol Therapeut, 7, 174-197. (Pubitemid 40354587)
89. Sieg A, Jeanneret F, Fathi M, Hochstrasser D, Rudaz S, Veuthey JL, Guy RH, Delgado-Charro MB. (2008). Extraction of amino acids by reverse iontophoresis: simulation of therapeutic monitoring in vitro. Eur J Pharm Biopharm, 70, 908-913.
90. Singh P, Roberts MS, Maibach HI. (1995). Modelling of plasma levels of drugs following transdermal iontophoresis. J Control Release, 33, 293-298.
91. Slough CL, Spinelli MJ, Kasting GB. (1988). Transdermal delivery of etodronate (EHDP) in the pig via iontophoresis. J Membr Sci, 35, 161-165. (Pubitemid 18010209)
92. Smith KJ, Konzelman FA, Lombardo FA, Skelton HG, Holland TT, Yeager J, Wagner KF, Oster CN, Chung R. (1992). Iontophoresis of vinblastine into normal skin and for treatment of Kaposi's sarcoma in human immunodeficiency virus-positive patients. The Military Consortium for Applied Retroviral Research. Arch Dermatol, 128, 1365-1370.
93. Sung KC, Fang JY, Hu OY. (2000). Delivery of nalbuphine and its prodrugs across skin by passive diffusion and iontophoresis. J Control Release, 67, 1-8. (Pubitemid 30201675)
94. Suzuki Y, Iga K, Yanai S, Matsumoto Y, Kawase M, Fukuda T, Adachi H, Higo N, Ogawa Y. (2001). Iontophoretic pulsatile transdermal delivery of human parathyroid hormone (1-34). J Pharm Pharmacol, 53, 1227-1234. (Pubitemid 32904017)
95. Sylvestre JP, Guy RH, Delgado-Charro MB. (2008). In vitro optimization of dexamethasone phosphate delivery by iontophoresis. Phys Ther, 88, 1177-1185.
96. Tamada JA, Bohannon NJ, Potts RO. (1995). Measurement of glucose in diabetic subjects using noninvasive transdermal extraction. Nat Med, 1, 1198-1201.
97. Thysman S, Hanchard C, Preat V. (1994). Human calcitonin delivery in rats by iontophoresis. J Pharm Pharmacol, 46, 725-730. (Pubitemid 24289660)
98. Tierney MJ, Tamada JA, Potts RO, Jovanovic L, Garg S; the Cygnus Research Team. (2001). Clinical evaluation of the GlucoWatch Biographer: a continual, non-invasive glucose monitor for patients with diabetes. Biosens Bioelectron, 16, 621-629. (Pubitemid 33000190)
99. Van der Geest R, van Laar T, Gubbens-Stibbe JM, Bodde HE, Danhof M. (1997). Iontophoretic delivery of apomorphine. An in vivo study in patients with Parkinson's disease. Pharm Res, 14, 1804-1810. (Pubitemid 28062929)
100. Volpato NM, Nicoli S, Laureri C, Colombo P, Santi P. (1998). In vitro acyclovir distribution in human skin layers after transdermal iontophoresis. J Control Release, 50, 291-296. (Pubitemid 28044124)
101. Wang Y, Thakur R, Fan Q, Michniak B. (2005). Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. Eur J Pharm Biopharm, 60, 179-191. (Pubitemid 40804560)
102. Wascotte V, Preat V. (2006). Topical delivery by iontophoresis. In: Paye M, Barel AO, Maibach HI, eds. Handbook of Cosmetic Science and Technology (pp. 189-200). 2nd ed. London, UK: Taylor & Francis.
103. Wascotte V, Rozet E, Salvaterra A, Hubert P, Jadoul M, Guy RH, Preat V. (2008). Non-invasive diagnosis and monitoring of chronic kidney disease by reverse iontophoresis of urea in vivo. Eur J Pharm Biopharm, 69, 1077-1082.
104. Wearley L, Lui JC, Chien YW. (1989). Iontophoresis-facilitated transdermal delivery of verapamil: II. Factors affecting reversibility of skin permeability. J Control Release, 9, 231-242. (Pubitemid 19203717)
105. Welch ML, Grabski WJ, McCollough ML, Skelton HG, Smith KJ, Menon PA. (1997). 5-Fluorouracil iontophoretic therapy for Bowen's disease. J Am Acad Dermatol, 36, 956-958. (Pubitemid 27265909)
106. Zakzewski CA, Li JK. (1991). Pulsed mode constant current iontophoretic transdermal metoprolol tartrate delivery in established acute hypertensive rabbits. J Control Release, 17, 157-162.
107. Zakzewski CA, Amory DW, Jasaitis DK, Li JK. (1992). Iontophoretically enhanced transdermal delivery of an ACE inhibitor in induced hypertensive rabbits: preliminary report. Cardiovasc Drugs Ther, 6, 589-595. (Pubitemid 23045361)